VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis

P. A. Muraro, T. Leist, B. Bielekova, H. F. McFarland

Research output: Contribution to journalArticlepeer-review

Abstract

Effects on adhesion molecules of immune cells might contribute to the mode of action of interferon-β (IFN-β) in multiple sclerosis (MS). We have serially monitored the cell surface expression of integrins CD49d (VLA-4) and CD11a (LFA-1) on fresh T lymphocyte subpopulations from 5 MS patients monthly for 2 months prior to treatment and for 3 months on treatment with IFN-β1b. In parallel, we assessed inflammatory disease activity by monthly contrast-enhanced magnetic resonance imaging (MRI). IFN-β treatment specifically downregulated CD49d expression on CD8+ and CD4+/CD45RO+ 'memory' T lymphocytes and differentially modulated the proportion of CD4+, CD8+ and CD27+ T cells. These effects may play an important role in the reduction of central nervous system cell trafficking and inflammation in MS. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)186-194
Number of pages9
JournalJournal of Neuroimmunology
Volume111
Issue number1-2
DOIs
StatePublished - Nov 1 2000
Externally publishedYes

Keywords

  • Adhesion molecules
  • Interferon-β
  • Multiple sclerosis
  • T lymphocytes
  • VLA-4

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Fingerprint Dive into the research topics of 'VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis'. Together they form a unique fingerprint.

Cite this